Avanir expects to raise more capital if Neurodex approved for marketing

By Ted A. Knutson

Washington, Dec. 14 - Avanir Pharmaceuticals Inc. said it expects to try to raise more capital if its drug Neurodex is approved for marketing by the Food and Drug Administration.

The company said potential alternatives for raising capital include, but are not limited to, partnering arrangements where partners share development costs, issuance of debt or equity securities under its June 2005 shelf registration statement, and licensing or sales of one or more of Avanir's platform technologies or new drug candidates.

Neurodex is a patented, orally administered combination of dextromethorphan and an enzyme inhibitor that sustains elevated levels of dextromethorphan with a once- or twice-daily dosing schedule. The drug is for use in pseudobulbar affect, PBA, also known as emotional lability, and neuropathic pain.

Avanir completed the submission of a "rolling" New Drug Application for Neurodex in the treatment of PBA in June 2005.

San Diego-based Avanir develops therapeutic treatments for chronic diseases.

The announcement was made in a 10-K filing with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.